Biocytogen’s RenMab Platform Wins Japanese Patent, Expanding IP Portfolio
China’s Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that its RenMab platform, a key...
Bayer’s Vividion Gains Global Rights to WRN Inhibitor VVD-214
German pharmaceutical giant Bayer AG (ETR: BAYN) announced that its wholly owned subsidiary Vividion Therapeutics,...
Nanjing Leads Biolabs Files for Hong Kong IPO Amid Product Pipeline Progress
China-based Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotech company focusing on oncology and autoimmune...
Acotec Scientific Gains NMPA Approval for AcoArt Verbena Vertebral Balloon
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has received marketing approval from China’s National Medical...
Hengrui Pharmaceuticals Gains NMPA Approval for Phase Ib/II Study of SHR-A1811, Adebrelimab and Famitinib in Solid Tumors
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...
Qure Biotechnology Secures RMB 100 Million Series C1 Financing
China-based Qure Biotechnology (Shanghai) Co., Ltd. announced the completion of a Series C1 financing round...
Lianhuan Pharma Gains NMPA Approval for No-Spa Generic
China-based Jiangsu Lianhuan Pharmaceutical Co., Ltd (SHA: 600513) announced that it has received market clearance...
Roche’s Evrysdi 5mg Tablet Gains EU Commission Approval for Spinal Muscular Atrophy
Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced that the European Commission (EC) has...
Shanghai OPM Biosciences Plans Acqusition of PharmaLegacy Labs for RMB 1.45 Billion
Shanghai OPM Biosciences Co., Ltd (SHA: 688293), a China-based cell culture-focused Contract Development and Manufacturing...
Sunshine Guojian’s SSGJ-613 Meets Phase III Endpoints in Acute Gouty Arthritis
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced...
NHSA Strengthens Pharmaceutical Pricing and Procurement Credit Evaluation Mechanism
The National Healthcare Security Administration (NHSA) issued a notification this week to refine its credit...
China Issues Whistleblower Incentives for Drug and Medical Device Safety Violations
China’s National Medical Products Administration (NMPA), Ministry of Finance (MoF), and State Administration for Market...
China’s National Health Commission Mandates Labor Pain Management Services Expansion
China’s National Health Commission (NHC) issued a notification mandating the comprehensive promotion of labor pain...
Intragrand Pharma Licenses Lenamilast to Transpire Bio for Global Development
China-based Suzhou Intragrand Pharma has entered into a licensing agreement with U.S.-headquartered Transpire Bio Inc....
Consun Pharma Partners with DP Technology to Accelerate AI-Driven Kidney Disease Drug R&D
China-based Consun Pharmaceutical Group Ltd (HKG: 1681) announced a strategic partnership with compatriot firm DP...
Innovent Biologics’ IBI363 Receives Breakthrough Therapy Designation from CDE
China-based Innovent Biologics, Inc. (HKG: 1801) announced that its first-in-class PD-1/IL-2α-bias bispecific antibody (BsAb) fusion...
BMS Secures NMPA Approval for Reblozyl in Myelodysplastic Syndromes
US-based multinational Bristol-Myers Squibb (BMS, NYSE: BMY) announced that it has received an indication extension...
Shanghai Pharma Partners with Chugai Pharma China to Enhance Bone Health Products
China’s Shanghai Pharmaceuticals Holding Co., Ltd. (HKG: 2607, SHA: 601607; SPH) has established a partnership...
Genrix Bio Partners with Cullinan Therapeutics for GR1803 License
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) announced a licensing agreement with Cullinan Therapeutics,...
AstraZeneca’s Imfinzi Approved for Limited Stage Small Cell Lung Cancer in China
UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) received approval from China’s National Medical Products Administration...